Michael Hayden - Articles and news items


Teva completes acquisition of Labrys

Industry news / 21 July 2014 / Teva

…opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.


Teva reports positive results from pivotal Phase III study to evaluate hydrocodone bitartrate extended-release tablets (CEP-33237) for moderate to severe chronic low back pain

Industry news / 30 April 2014 / Teva

Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with potential abuse-deterrent properties…


Teva and OncoGenex announce top-line survival results of Phase III SYNERGY trial evaluating custirsen in combination with first-line docetaxel and prednisone for metastatic castrate-resistant prostate cancer

Industry news / 28 April 2014 / Teva

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial…


New data presented at 29th ECTRIMS Congress reinforce the clinical profile of investigational laquinimod on disease progression and inflammation in relapsing-remitting multiple sclerosis

Industry news / 4 October 2013 / Teva Pharmaceutical Industries Ltd

Pooled data analysis of Phase III ALLEGRO and BRAVO studies add to our understanding of investigational laquinimod for relapsing-remitting Multiple Sclerosis…


Teva to present further results of twenty-year open-label extension study of glatiramer acetate 20 mg daily for relapsing-remitting Multiple Sclerosis

Industry news / 3 October 2013 / Teva Pharmaceutical Industries Ltd

“To our knowledge, glatiramer acetate is the only treatment for multiple sclerosis that has been prospectively studied for nearly two decades…”


Newly published phase III exploratory analysis suggests investigational oral laquinimod for multiple sclerosis may reduce brain damage caused by neurodegeneration

Industry news / 1 October 2013 / Teva Pharmaceutical Industries Ltd

“This Phase III sub-study was pre-planned to explore the ability of laquinimod to act on mechanisms leading to irreversible brain tissue damage…”


Teva reports top-line results from final Phase III study of armodafinil (NUVIGIL®) in patients with major depression associated with bipolar I disorder

Industry news, News / 30 August 2013 / Teva Pharmaceutical Industries Ltd

TEVA announced top-line results of its final Phase III clinical study for armodafinil (NUVIGIL®)…


Teva receives European Marketing Authorization for Lonquex® (XM22 lipegfilgrastim)

Industry news, News / 8 August 2013 / Teva Pharmaceutical Industries Ltd

TEVA announced that the European Commission has granted marketing authorization for Lonquex® (lipegfilgrastim)…


Teva’s Lonquex® (XM22 lipegfilgrastim) recommended for approval in the EU

Industry news, News / 3 June 2013 / Teva Pharmaceutical Industries Ltd

Teva’s Lonquex® (XM22 lipegfilgrastim) recommended for approval in the EU for the reduction of CIN…


Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week

Industry news, News / 30 May 2013 / Teva Pharmaceutical Industries Ltd.

“We are pleased that the FDA has accepted for review our sNDA…”


Teva and Xenon announce FDA orphan drug designation for pain drug XEN402

Industry news, News / 23 April 2013 / TEVA

“We are very pleased to receive orphan drug designation for XEN402…”


Teva Pharmaceutical’s new investigational treatment for MS

Industry news, News / 21 March 2013 / PARADIGM COMMUNICATIONS

TEVA and Active Biotech announced top-line results from the open-label extension of the Phase III ALLEGRO study…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...